Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 – Science

1Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD; 2Fungal Pathogenesis Section Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD; 3Willamette Valley Cancer Institute and Research Center, US Oncology, Eugene, OR; 4Hematology-Oncology Department, Walter Reed National Military Medical Center, Bethesda, MD; 5John Theurer Cancer Center, Hackensack Meridian and School of Medicine at Seton Hall, NJ; 6Rocky Mountain Cancer Center, US Oncology, Colorado Springs, CO; 7Department of Emergency Medicine, Penrose-St. Francis Health Services, Colorado Springs, CO; US Acute Care Solutions, Canton, OH; 8Department of Medicine, St. Peters Hospital and US Oncology, Albany, NY; 9Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD; 10Acerta Pharma, South San Francisco, CA; 11Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD, USA 12AstraZeneca, One MedImmune Way, Gaithersburg, MD

Read more from the original source:

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 - Science